Director, HCP Marketing

Who We Are

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.

Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.

In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN
1701 (targeting Nav
1.7) and XEN
1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

The Director, HCP Marketing, will lead the development and execution of HCP education strategy to support brand objectives and drive appropriate product adoption across the US market. This role sits within US HCP Marketing and is responsible for delivering high-impact, compliant educational initiatives that improve disease understanding, clinical practice, and confidence in product use.

This individual will serve as a strategic partner during launch and pre-launch, ensuring education programs are insight-driven, differentiated, and tightly aligned with brand strategy and customer experience priorities.

This role is critical to shaping how healthcare providers understand, adopt, and ultimately deliver innovative therapies to patients. The Director will play a pivotal role in ensuring education is not only scientifically rigorous but also strategically differentiated—driving meaningful impact for both patients and the brand.

The position reports to the Senior Director, HCP Marketing, and will be based out of Boston, MA, USA in our Needham office. We will consider remote locations for exceptional candidates. Hybrid positions require a minimum of two onsite days per week.

• Lead the development of the US HCP education strategy aligned to brand goals, lifecycle stage (including launch-readiness), and key customer segments.
• Translate brand strategy, positioning, and customer insights into actionable, differentiated education plans.
• Identify priority HCP segments (specialists, community providers, advanced practice providers, etc.) and tailor education approaches accordingly.
• Serve as the education lead in brand planning, ensuring strong integration across omnichannel touchpoints.

• Oversee the design and execution of HCP education programs, including:
  • Peer-to-peer programs and speaker bureaus
  • Congress strategy and educational presence
  • Workshops, advisory boards, and training events
  • Digital and on-demand learning platforms
• Develop compelling, insight-driven educational content aligned to clinical data and brand narrative.
• Ensure consistent and…